Contact this trialFirst, we need to learn more about you.
Antisense Oligonucleotide
High-Dose Nusinersen for Spinal Muscular Atrophy
Recruiting2 awardsPhase 3
Baltimore, Maryland
This trial is testing a higher dose of nusinersen, a drug used to treat spinal muscular atrophy (SMA). The objectives are to see if the higher dose is more effective and safe than the current approved dose, as measured by the CHOP-INTEND score.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service